{
      "Rank": 219,
      "Acronym": [
            "MSCsTreatPBC"
      ],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Patients who have primary biliary cirrhosis.",
            "Patients who have primary biliary cirrhosis."
      ],
      "ArmGroupInterventionName": [
            "Biological: Biological: mesenchymal stem cell",
            "Drug: ursodeoxycholic acid"
      ],
      "ArmGroupLabel": [
            "allogenic mesenchymal stem cells (MSCs)",
            "ursodeoxycholic acid (UDCA)"
      ],
      "ArmGroupType": [
            "Experimental",
            "Active Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT01440309"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The study is designed to evaluate the safety and efficacy of intravenous administration of bone marrow derived mesenchymal stem cells for patients with refractory primary biliary cirrhosis (PBC)."
      ],
      "BriefTitle": [
            "Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Refractory Primary Biliary Cirrhosis"
      ],
      "CentralContactEMail": [
            "zhangfccra@yahoo.com.cn",
            "yangyunjiao81@163.com"
      ],
      "CentralContactName": [
            "Fengchun Zhang, MD",
            "Yunjiao Yang, MD"
      ],
      "CentralContactPhone": [
            "0086-10-65296891",
            "0086-10-65295047"
      ],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [
            "Contact",
            "Contact"
      ],
      "CollaboratorClass": [
            "OTHER"
      ],
      "CollaboratorName": [
            "Peking Union Medical College Hospital"
      ],
      "CompletionDate": [
            "December 2013"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Primary Biliary Cirrhosis"
      ],
      "ConditionAncestorId": [
            "D000010335",
            "D000008107",
            "D000004066",
            "D000002780",
            "D000002779",
            "D000001649",
            "D000001660"
      ],
      "ConditionAncestorTerm": [
            "Pathologic Processes",
            "Liver Diseases",
            "Digestive System Diseases",
            "Cholestasis, Intrahepatic",
            "Cholestasis",
            "Bile Duct Diseases",
            "Biliary Tract Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC06",
            "BC23",
            "All",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Digestive System Diseases",
            "Symptoms and General Pathology",
            "All Conditions",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Cirrhosis",
            "Primary Biliary Cirrhosis",
            "Cirrhosis",
            "Primary Biliary Cirrhosis"
      ],
      "ConditionBrowseLeafId": [
            "M10255",
            "M10257",
            "M7637",
            "M10259",
            "M8035",
            "M6407",
            "M5171",
            "M5172",
            "M4087",
            "M4098",
            "T4683"
      ],
      "ConditionBrowseLeafName": [
            "Liver Cirrhosis",
            "Liver Cirrhosis, Biliary",
            "Fibrosis",
            "Liver Diseases",
            "Gastrointestinal Diseases",
            "Digestive System Diseases",
            "Cholestasis",
            "Cholestasis, Intrahepatic",
            "Bile Duct Diseases",
            "Biliary Tract Diseases",
            "Primary Biliary Cholangitis"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "high"
      ],
      "ConditionMeshId": [
            "D000008103",
            "D000008105",
            "D000005355"
      ],
      "ConditionMeshTerm": [
            "Liver Cirrhosis",
            "Liver Cirrhosis, Biliary",
            "Fibrosis"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "Primary biliary cirrhosis (PBC) is an organ-specific inflammatory disease and characterized by immune mediated destruction of intrahepatic bile ducts, then lead to liver cirrhosis and eventually failure.Currently, ursodeoxycholic acid (UDCA) is the only drug approved by the Food and Drug Administration (FDA). Novel treatment is urgently needed for patients who have an incomplete response to UDCA. Mesenchymal stem cells (MSC) represent a promising tool for cell-based therapies of autoimmune diseases. To explore the therapeutic effect of MSCs for PBC, the investigators plan to conduct an open-label, randomized clinical trial. Patients with PBC will be enrolled and randomly divided into two groups which will receive MSCs and UDCA respectively. The investigators will evaluate the efficacy and safety of MSCs for PBC by comparison of symptom improvement, survival rate and side effects in the two groups."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nThere must be at least two of the following: a concentration in serum of AMAs at titres of 1:40 or higher; an unexplained rise in the amount of alkaline phosphatase of at least 1\u20225 times the upper limit of normal for more than 24 weeks; and compatible liver histological findings, specifically non-suppurative cholangitis and interlobular bile duct injury.\nIncomplete response to UDCA at 13-15 mg/kg/day, Criteria for the group of complete responders is including: concentrations of alkaline phosphatase less than three times the upper limit of normal, aspartate aminotransferase less than twice the upper limit of normal, and bilirubin less than 17 \u03bcmol/L;and normalisation of abnormal concentrations of bilirubin, albumin, or both.\nLiver pathological staging in 2 or3, Histological staging is based on Ludwig's and Scheuer's classifications\n\nExclusion Criteria:\n\nPatients are receiving any other investigational agents within 4 weeks of study entry\nUncontrolled intercurrent illness including, but not limited to, ongoing or active infection (defined as invasive fungal infection and progressive CMV viremia), symptomatic congestive heart failure (NYH class III and IV), unstable angina pectoris, or cardiac arrhythmia\nIn pregnancy or lactation\nPsychiatric illness or mental deficiency making compliance with treatment or informed consent impossible\nHCVpositive \uff0cHBSAg positive or with other liver diseases\nCombined with other autoimmune disease\nExpected survival time is less than one year\nDecompensation of liver function\uff08Child B or C\uff09\nHave a history of allergy or Allergic constitution"
      ],
      "EnrollmentCount": [
            "20"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [
            "D000002756",
            "D000005765"
      ],
      "InterventionAncestorTerm": [
            "Cholagogues and Choleretics",
            "Gastrointestinal Agents"
      ],
      "InterventionArmGroupLabel": [
            "allogenic mesenchymal stem cells (MSCs)",
            "ursodeoxycholic acid (UDCA)"
      ],
      "InterventionBrowseBranchAbbrev": [
            "Gast",
            "All"
      ],
      "InterventionBrowseBranchName": [
            "Gastrointestinal Agents",
            "All Drugs and Chemicals"
      ],
      "InterventionBrowseLeafAsFound": [
            "Ester"
      ],
      "InterventionBrowseLeafId": [
            "M16481",
            "M8033"
      ],
      "InterventionBrowseLeafName": [
            "Ursodeoxycholic Acid",
            "Gastrointestinal Agents"
      ],
      "InterventionBrowseLeafRelevance": [
            "high",
            "low"
      ],
      "InterventionDescription": [
            "Mesenchymal stem cells,5-50 million/kg, Intravenous infusion, One dosage\uff0cwhether to give another dosage depending on patients' condition",
            "13-15 mg/kg/day, to the end of the study"
      ],
      "InterventionMeshId": [
            "D000014580"
      ],
      "InterventionMeshTerm": [
            "Ursodeoxycholic Acid"
      ],
      "InterventionName": [
            "Biological: mesenchymal stem cell",
            "ursodeoxycholic acid"
      ],
      "InterventionOtherName": [
            "regenerative medicine:MSCs",
            "UDCA"
      ],
      "InterventionType": [
            "Biological",
            "Drug"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "biliary cirrhosis"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [
            "Recruiting"
      ],
      "LastUpdatePostDate": [
            "August 3, 2012"
      ],
      "LastUpdatePostDateType": [
            "Estimate"
      ],
      "LastUpdateSubmitDate": [
            "August 1, 2012"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Robert Chunhua Zhao, MD, PhD"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Beijing"
      ],
      "LocationContactEMail": [
            "zhangfccra@yahoo.com.cn"
      ],
      "LocationContactName": [
            "Fengchun Zhang, MD"
      ],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [
            "Contact"
      ],
      "LocationCountry": [
            "China"
      ],
      "LocationFacility": [
            "Peking Union Medical College Hospital"
      ],
      "LocationState": [],
      "LocationStatus": [
            "Recruiting"
      ],
      "LocationZip": [],
      "MaximumAge": [
            "60 Years"
      ],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Phase I Clinical Trial, Randomized, Controlled, to Evaluate the Efficacy and Safety of Therapy With Allogenic Mesenchymal Stem Cells From Bone Marrow for Patients With Refractory Primary Biliary Cirrhosis"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Chinese Academy of Medical Sciences"
      ],
      "OrgStudyId": [
            "2008BAI59B03/2011AA020119"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Peking Union Medical College Hospital",
            "Chinese Academy of Medical Sciences"
      ],
      "OverallOfficialName": [
            "Fengchun Zhang, MD",
            "Robert Chunhua Zhao, MD,PhD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator",
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Unknown status"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "November 2013"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "Serum level of alkaline phosphatase will be measured at entry, 1 months\uff0c3 months, 6 months and 24 months after therapy"
      ],
      "PrimaryOutcomeMeasure": [
            "serum level of alkaline phosphatase"
      ],
      "PrimaryOutcomeTimeFrame": [
            "24 months after MSCs administration"
      ],
      "ReferenceCitation": [
            "Sun Z, Han Q, Zhu Y, Li Z, Chen B, Liao L, Bian C, Li J, Shao C, Zhao RC. NANOG has a role in mesenchymal stem cells' immunomodulatory effect. Stem Cells Dev. 2011 Sep;20(9):1521-8. doi: 10.1089/scd.2010.0366. Epub 2011 Feb 26.",
            "Shi D, Liao L, Zhang B, Liu R, Dou X, Li J, Zhu X, Yu L, Chen D, Zhao RC. Human adipose tissue-derived mesenchymal stem cells facilitate the immunosuppressive effect of cyclosporin A on T lymphocytes through Jagged-1-mediated inhibition of NF-\u03baB signaling. Exp Hematol. 2011 Feb;39(2):214-224.e1. doi: 10.1016/j.exphem.2010.10.009. Epub 2010 Nov 13.",
            "Zhang B, Liu R, Shi D, Liu X, Chen Y, Dou X, Zhu X, Lu C, Liang W, Liao L, Zenke M, Zhao RC. Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population. Blood. 2009 Jan 1;113(1):46-57. doi: 10.1182/blood-2008-04-154138. Epub 2008 Oct 2.",
            "Liao L, Zhao RC. An overview of stem cell-based clinical trials in China. Stem Cells Dev. 2008 Aug;17(4):613-8. doi: 10.1089/scd.2008.0183. Review.",
            "Fang B, Shi M, Liao L, Yang S, Liu Y, Zhao RC. Systemic infusion of FLK1(+) mesenchymal stem cells ameliorate carbon tetrachloride-induced liver fibrosis in mice. Transplantation. 2004 Jul 15;78(1):83-8.",
            "Wang J, Bian C, Liao L, Zhu Y, Li J, Zeng L, Zhao RC. Inhibition of hepatic stellate cells proliferation by mesenchymal stem cells and the possible mechanisms. Hepatol Res. 2009 Dec;39(12):1219-28. doi: 10.1111/j.1872-034X.2009.00564.x. Epub 2009 Sep 25.",
            "Chen L, Zhang W, Yue H, Han Q, Chen B, Shi M, Li J, Li B, You S, Shi Y, Zhao RC. Effects of human mesenchymal stem cells on the differentiation of dendritic cells from CD34+ cells. Stem Cells Dev. 2007 Oct;16(5):719-31.",
            "Deng W, Han Q, Liao L, You S, Deng H, Zhao RC. Effects of allogeneic bone marrow-derived mesenchymal stem cells on T and B lymphocytes from BXSB mice. DNA Cell Biol. 2005 Jul;24(7):458-63.",
            "Deng W, Han Q, Liao L, Li C, Ge W, Zhao Z, You S, Deng H, Zhao RC. Allogeneic bone marrow-derived flk-1+Sca-1- mesenchymal stem cells leads to stable mixed chimerism and donor-specific tolerance. Exp Hematol. 2004 Sep;32(9):861-7.",
            "Zhang W, Ge W, Li C, You S, Liao L, Han Q, Deng W, Zhao RC. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev. 2004 Jun;13(3):263-71."
      ],
      "ReferencePMID": [
            "21235326",
            "21078360",
            "18832657",
            "18673001",
            "15257043",
            "19788697",
            "17999594",
            "16008514",
            "15345288",
            "15186722"
      ],
      "ReferenceType": [
            "background",
            "background",
            "background",
            "background",
            "background",
            "background",
            "background",
            "background",
            "background",
            "background"
      ],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [
            "Chinese Academy of Medical Sciences"
      ],
      "ResponsiblePartyInvestigatorFullName": [
            "Robert Chunhua Zhao, MD, PhD"
      ],
      "ResponsiblePartyInvestigatorTitle": [
            "MD, PhD\uff0cProfessor of medicine"
      ],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor-Investigator"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "Liver biopsy of each patient will be taken before entry into therapeutic trials and at 6 months after therapy.",
            "serum levels of TNF-alpha will be assessed before entry into therapeutic trials and at 6 months after therapy",
            "changes in fatigue will be evaluated before test (baseline), 1 month,3 months and 6 months after theraphy by PBC-40 score.",
            "serum levels of Interleukin will be assessed before entry into therapeutic trials and at 6 months after therapy",
            "changes in pruritus severity will be evaluated before test (baseline), 1 month,3 months and 6 months after theraphy by VAS score."
      ],
      "SecondaryOutcomeMeasure": [
            "histological changes in liver biopsies",
            "Serum levels of TNF-alpha",
            "changes in fatigue",
            "The occurrence of cirrhosis and its complications",
            "Serum levels of Interleukin",
            "changes in pruritus severity"
      ],
      "SecondaryOutcomeTimeFrame": [
            "6 months after therapy",
            "6 months after therapy",
            "6 months after theraphy",
            "24 months after therapy",
            "6 months after therapy",
            "6 months after therapy"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "November 2011"
      ],
      "StartDateType": [],
      "StatusVerifiedDate": [
            "September 2011"
      ],
      "StdAge": [
            "Adult"
      ],
      "StudyFirstPostDate": [
            "September 26, 2011"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "September 20, 2011"
      ],
      "StudyFirstSubmitQCDate": [
            "September 23, 2011"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}